Monoiodobenzoic acid compound and application thereof in resisting ADV7 virus

A technology of iodobenzoic acid and iodobenzoic acid, which is applied in the direction of antiviral agents, medical preparations containing active ingredients, and pharmaceutical formulas, can solve the problems of unreported inhibitory activity, and achieve easy large-scale production promotion and synthesis Simple process, economical and fast effect

Active Publication Date: 2020-04-17
HUBEI UNIV OF TECH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antiviral activity of iodocarboxylic acids, including the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoiodobenzoic acid compound and application thereof in resisting ADV7 virus
  • Monoiodobenzoic acid compound and application thereof in resisting ADV7 virus
  • Monoiodobenzoic acid compound and application thereof in resisting ADV7 virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] [Example 1] Research experiment on anti-ADV7 activity of monoiodobenzoic acid compounds L1-L3

[0031] In the present embodiment, the anti-ADV7 activity research experiment was carried out to the above-mentioned compound, and the experimental situation is as follows:

[0032] 1. Test content:

[0033] Anti-ADV7 activity analysis of compounds: In the present invention, the anti-ADV7 activity of monoiodobenzoic acid will be evaluated by combining cytopathic effect analysis and MTT assay cell survival rate detection method.

[0034] 2. Test method:

[0035] 2.1.1 Toxicity of compounds to host Hela cells

[0036] Hela cells were plated in 96-well plates at 37°C, 5% CO 2 After the monolayer was grown in the incubator, the cell culture solution was discarded, and the cell maintenance solution containing different concentrations of the test compound was added to continue the culture. After 48 hours, the cytotoxicity was visually observed under the microscope and recorded re...

Embodiment 2

[0048] [Example 2] Inhibition test of monoiodobenzoic acid compounds L1, L3 on ADV7 progeny virus output

[0049] In this embodiment, monoiodobenzoic acid has been carried out in-depth research on the anti-ADV7 activity, and the inhibitory effect test of compounds L1 and L3 on the production of ADV7 progeny virus has been carried out. The test conditions are as follows:

[0050] 1. Test content

[0051] After ADV7 infected Hela cells, the inhibitory effect of compounds L1 and L3 on the production of ADV7 progeny virus was detected.

[0052] 2. Test method

[0053] Hela cells in the logarithmic growth phase were plated in 24-well plates, and 100TCID after the monolayer was overgrown 50 ADV7 infected cells, incubated at 37°C for 1.5h, removed the virus solution, washed three times with PBS, and added cell maintenance solution containing 25 μg / mL L1 and 50 μg / mL L3. After 48 hours, the cells and supernatant were collected and lysed by freezing and thawing three times at -20°C ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a monoiodobenzoic acid compound and an application thereof in resisting ADV7 virus. Through the research experiments on anti-ADV7 activity by monoiodobenzene comprising o-iodobenzoic acid (L1), m-iodobenzoic acid (L2) and p-iodobenzoic acid (L3), the compounds L1 and L3 inhibit cytopathic effect (CPE) generated by ADV7 on host cells Hela, enhance cell survival rate and reduce filial generation virus yield, and can be applied to preparation of anti-ADV7 virus drugs.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to a monoiodobenzoic acid compound and its application in anti-ADV7 virus. Background technique [0002] Adenoviruses (adenoviruses, ADVs) are a group of widely distributed DNA viruses. There are 52 known species of somatic adenoviruses, named ADV1-ADV52 respectively, divided into two genera, with a total of more than 100 serotypes. About one-third of the known serotypes of human adenoviruses are associated with human disease. Adenoviruses can invade various tissues and organs such as the respiratory tract, conjunctiva, gastrointestinal tract, and urinary tract. The main infection is the respiratory tract. In severe cases, it can cause pneumonia in children and accumulate in various systems of the body. Adenoviral pneumonia caused by adenovirus infection is one of the most serious types of pneumonia in children. The adenovirus types associated with respiratory diseases ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P31/14
CPCA61K31/192A61P31/14
Inventor 王龙胜王悦魏艳红李妮朱茂春郭超袁子月冯治坤
Owner HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap